Natalia Murinova is a Neurology physician affiliated with University of Washington. OpenAlex indexes 110 publications with 567 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1959 NE Pacific Street
Box 356097
Seattle, WA 98195
Telephone
206-598-6950Registry record last updated 19 Jun 2013.
Clinical trials
- Aspirin Resistance in Women With Migraine
Sponsor: Swedish Medical Center
- Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)
Sponsor: Swedish Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- IMPEL PHARMACEUTICALS INC.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
84.6%N-methyl-D-aspartate Receptor Antagonist30.2%Memantine Hcl100%Part D≥32 patientsGabapentinoids19.5%Gabapentin77%Pregabalin23%Part D<11 patients+ 5 more classes in this area
Cardiovascular
9.8%Beta blocker9.8%Propranolol Hcl72%Nadolol28%Part D<11 patientsMusculoskeletal
5.7%Nonsteroidal Anti-inflammatory Drug5.7%Indomethacin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cognitive Dysfunction in Migraine: Underlying Mechanisms and Clinical Implications
Current Pain and Headache Reports
2026 - The Utility of a Novel, Combined Biofeedback-Virtual Reality Device as Add-on Treatment for Chronic Migraine
Clinical Journal of Pain
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Rainer Storb
University of Washington
Connie Celum, MD, MPH
University of Washington
Helen Chu, MD, MPH
University of Washington
Bryan Kestenbaum, MD
University of Washington
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”